Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis

European Journal of Cancer Care

Volumn 26, Issue 5, 2017, Pages

  Peng, L ^a   Bu, Z ^b   Ye, X ^a   Zhou, Y ^c   Zhao, Q ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG HOSPITAL   (China)

^c Food and Drug Administration   (China)

Author keywords

meta analysis; nab paclitaxel; peripheral neuropathy

Indexed keywords

130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; PACLITAXEL; TAXOID;

CHEMICALLY INDUCED; HUMAN; INCIDENCE; META ANALYSIS; NEOPLASM; PERIPHERAL NEUROPATHY; RISK; SEVERITY OF ILLNESS INDEX;

ALBUMINS; ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RISK; SEVERITY OF ILLNESS INDEX; TAXOIDS;

EID: 84949023975     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12407     Document Type: Article

References (42)

1. Alberts D.S., Blessing J.A., Landrum L.M., Warshal D.P., Martin L.P., Rose S.L., Bonebrake A.J. & Ramondetta L.M. (2012) Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecologic Oncology 127, 451–455.
2. Balayssac D., Ferrier J., Descoeur J., Ling B., Pezet D., Eschalier A. & Authier N. (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opinion on Drug Safety 10, 407–417.
3. Begg C.B. & Mazumdar M. (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101.
4. Blum J.L., Savin M.A., Edelman G., Pippen J.E., Robert N.J., Geister B.V., Kirby R.L., Clawson A. & O'Shaughnessy J.A. (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clinical Breast Cancer 7, 850–856.
5. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E. & Bellmunt J. (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Journal of Clinical Oncology 28, 2280–2285.
6. Coleman R.L., Brady W.E., McMeekin D.S., Rose P.G., Soper J.T., Lentz S.S., Hoffman J.S. & Shahin M.S. (2011) A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 122, 111–115.
7. Conlin A.K., Seidman A.D., Bach A., Lake D., Dickler M., D'Andrea G., Traina T., Danso M., Brufsky A.M., Saleh M., Clawson A. & Hudis C.A. (2010) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 10, 281–287.
8. ™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. EJC Supplements 8, 1–10.
9. Desai A.V., Marks G. & Grunstein R. (2003) Does sleep deprivation worsen mild obstructive sleep apnea? Sleep 26, 1038–1041.
10. Desai N., Trieu V., Damascelli B. & Soon-Shiong P. (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Translational Oncology 2, 59–64.
11. Egger M., Davey Smith G., Schneider M. & Minder C. (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629–634.
12. Forsyth P.A., Balmaceda C., Peterson K., Seidman A.D., Brasher P. & Deangelis L.M. (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Journal of Neuro-oncology 35, 47–53.
13. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M. & O'Shaughnessy J. (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology 23, 7794–7803.
14. Gradishar W.J., Krasnojon D., Cheporov S., Makhson A.N., Manikhas G.M., Clawson A. & Bhar P. (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. Journal of Clinical Oncology 27, 3611–3619.
15. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., Cristofanilli M., Booser D.J., Pusztai L., Rivera E., Theriault R.L., Carter C., Frye D., Hunt K.K., Symmans W.F., Strom E.A., Sahin A.A., Sikov W. & Hortobagyi G.N. (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of Clinical Oncology 23, 5983–5992.
16. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P. & Hawkins M.J. (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Annals of Oncology 17, 1263–1268.
17. Gutierrez-Gutierrez G., Sereno M., Miralles A., Casado-Saenz E. & Gutierrez-Rivas E. (2010) Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clinical and Translational Oncology 12, 81–91.
18. Hersh E.M., O'Day S.J., Ribas A., Samlowski W.E., Gordon M.S., Shechter D.E., Clawson A.A. & Gonzalez R. (2010) A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 116, 155–163.
19. Hosein P.J., de Lima Lopes G., Pastorini V.H. Jr, Gomez C., Macintyre J., Zayas G., Reis I., Montero A.J., Merchan J.R. & Rocha Lima C.M. (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. American Journal of Clinical Oncology, 36, 151–156.
20. Huang T.C. & Campbell T.C. (2012) Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treatment Reviews 38, 613–617.
21. Ibrahim N.K., Desai N., Legha S., Soon-Shiong P., Theriault R.L., Rivera E., Esmaeli B., Ring S.E., Bedikian A., Hortobagyi G.N. & Ellerhorst J.A. (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clinical Cancer Research 8, 1038–1044.
22. Ibrahim N.K., Samuels B., Page R., Doval D., Patel K.M., Rao S.C., Nair M.K., Bhar P., Desai N. & Hortobagyi G.N. (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. Journal of Clinical Oncology 23, 6019–6026.
23. Ko Y.J., Canil C.M., Mukherjee S.D., Winquist E., Elser C., Eisen A., Reaume M.N., Zhang L. & Sridhar S.S. (2013) Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. The Lancet Oncology 14, 769–776.
24. Kolevska T., Ryan C.J., Huey V., Weisberg L., Wang S., Baer D., Ghadialy A., Goldstein D., Fireman B. & Fehrenbacher L. (2009) Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC). 2009 ASCO Annual Meeting, Journal of Clinical Oncology 27, 15s (suppl.; abstr 5152).
25. Lobo C., Lopes G., Baez O., Castrellon A., Ferrell A., Higgins C., Hurley E., Hurley J., Reis I., Richman S., Seo P., Silva O., Slingerland J., Tukia K., Welsh C. & Gluck S. (2010) Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment 123, 427–435.
26. Mauri D., Kamposioras K., Tsali L., Bristianou M., Valachis A., Karathanasi I., Georgiou C. & Polyzos N.P. (2010) Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treatment Reviews 36, 69–74.
27. Mirtsching B., Cosgriff T., Harker G., Keaton M., Chidiac T. & Min M. (2011) A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clinical Breast Cancer 11, 121–128.
28. Paik P.K., James L.P., Riely G.J., Azzoli C.G., Miller V.A., Ng K.K., Sima C.S., Heelan R.T., Kris M.G., Moore E. & Rizvi N.A. (2011) A phase 2 study of weekly albumin-bound paclitaxel (Abraxane(R)) given as a two-hour infusion. Cancer Chemotherapy and Pharmacology 68, 1331–1337.
29. Preston C., Ashby D. & Smyth R. (2004) Adjusting for publication bias: modelling the selection process. Journal of Evaluation in Clinical Practice 10, 313–322.
30. Rivera E., Mejia J.A., Arun B.K., Adinin R.B., Walters R.S., Brewster A., Broglio K.R., Yin G., Esmaeli B., Hortobagyi G.N. & Valero V. (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112, 1455–1461.
31. Rizvi N.A., Riely G.J., Azzoli C.G., Miller V.A., Ng K.K., Fiore J., Chia G., Brower M., Heelan R., Hawkins M.J. & Kris M.G. (2008) Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. Journal of Clinical Oncology 26, 639–643.
32. Rugo H.S., Barry W.T., Moreno-Aspitia A., Lyss A.P., Cirrincione C., Mayer E.L., Naughton M., Layman R.M. & Carey L.A. (2012) CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol, 30, 2012, (suppl; abstr CRA1002).
33. Sasaki Y., Nishina T., Yasui H., Goto M., Muro K., Tsuji A., Koizumi W., Toh Y., Hara T. & Miyata Y. (2014) Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Science 105, 812–817.
34. Shepard D.R., Dreicer R., Garcia J., Elson P., Magi-Galluzzi C., Raghavan D., Stephenson A.J. & Klein E.A. (2009) Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. Journal of Urology, 181, 1672–1677; discussion 1677.
35. Socinski M.A., Bondarenko I., Karaseva N.A., Makhson A.M., Vynnychenko I., Okamoto I., Hon J.K., Hirsh V., Bhar P., Zhang H., Iglesias J.L. & Renschler M.F. (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. Journal of Clinical Oncology 30, 2055–2062.
36. Stubblefield M.D., Burstein H.J., Burton A.W., Custodio C.M., Deng G.E., Ho M., Junck L., Morris G.S., Paice J.A., Tummala S. & von Roenn J.H. (2009) NCCN task force report: management of neuropathy in cancer. Journal of the National Comprehensive Cancer Network, 7 suppl, S1–S26; quiz S27–8.
37. Tabernero J., Climent M.A., Lluch A., Albanell J., Vermorken J.B., Barnadas A., Anton A., Laurent C., Mayordomo J.I., Estaun N., Losa I., Guillem V., Garcia-Conde J., Tisaire J.L. & Baselga J. (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Annals of Oncology 15, 1358–1365.
38. Takiuchi H., Sasaki Y., Nishina T., Yasui H., Muro K., Tsuji A., Wasaburo K., Toh Y., Hara T. & Miyata Y. (2012) ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study. ASCO Meeting Abstracts, 30 (suppl. 4; abstract 90).
39. Teneriello M.G., Tseng P.C., Crozier M., Encarnacion C., Hancock K., Messing M.J., Boehm K.A., Williams A. & Asmar L. (2009) Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. Journal of Clinical Oncology 27, 1426–1431.
40. Windebank A.J. & Grisold W. (2008) Chemotherapy-induced neuropathy. Journal of the Peripheral Nervous System 13, 27–46.
41. Yusuf S., Peto R., Lewis J., Collins R. & Sleight P. (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 27, 335–371.
42. Zintzaras E. & Ioannidis J.P. (2005) Heterogeneity testing in meta-analysis of genome searches. Genetic Epidemiology 28, 123–137.